

CURRICULUM VITAE	
INFORMAZIONI PERSONALI	
Nome	Diego Ripamonti
E-mail	
Nazionalità	Italiana
Codice fiscale	
Data e luogo di nascita	
Indirizzo lavoro	

ESPERIENZA LAVORATIVA	
• Data	dal 2000 – ad oggi
• Nome e indirizzo del datore di lavoro	ASST Papa Giovanni XXXIII P.za OMS 24127 (BG)
• Tipo di azienda o settore	AZIENDA SOCIO SANITARIA TERRITORIALE
• Tipo di impiego	Dirigente Medico a rapporto esclusivo a tempo indeterminato
• Principali mansioni e responsabilità	POSIZIONE FUNZIONALE : 01/06/2017 al 31/05/2020: Incarico professionale di Alta Specializzazione Ca 01/06/2020 al 31/05/2025: Incarico professionale di Alta Specializzazione Ca Dal 16/06/2025 l'incarico dirigenziale professionale di Altissima Professionalità quale articolazione interna di struttura complessa (Ce SS) denominato "Terapia antivirale e farmaci antivirali innovativi" presso la SC Malattie infettive. Attività attuale Sostituto del Direttore della SC di M infettive. Attività di ambulatorio della coorte di pazienti con infezione cronica da HIV e coinfezione da HBV e HCV. Consulenza di terapia antiretrovirale per pediatria e ostetricia. Partecipazione alla attività di degenza e consulenze in PS. Responsabile della compilazione SDO dal 2014 ad oggi. Utilizzo FIBROSCAN® Principal Investigator in trials di terapia antiretrovirale. Stesura di protocolli di studio. Implementazione/coordinamento di studi clinici di coorte nella popolazione HIV. Scrittura di abstracts, relazioni e lavori scientifici per riviste internazionali indicizzate. Presentazioni ai congressi dei risultati. Responsabile per la organizzazione del corso di aggiornamento annuale su HIV e immunodeficit dal 2012 ad oggi per l'aggiornamento obbligatorio degli specialisti di Malattie Infettive presso hpg23. Coordinamento degli studenti di medicina nel training, preparazione tesi, nonché correlatore di tesi per gli esami di laurea in Medicina ed esami di specialità in Malattie infettive (presso Università degli studi di Milano). In passato Coordinatore della degenza di Malattie infettive durante l'emergenza COVID nel 2020 presso l'ospedale da campo (Fiera di Bergamo).

	Responsabile dell'attività di ricerca clinica durante il periodo COVID (Trial di remdesivir e coordinamento raccolta dati) 2020-21 Dal 2015-21 sostituto del Direttore della SC con coordinamento di riunioni di reparto (3 alla settimana) per la discussione di casi clinici. Sostituito del Direttore nel caso di AUDIT interna per la gestione del rischio Clinico (procedura di root cause analysis). Assistenza al medico legale (dr M. Marchesi) in un caso di contenzioso per il decesso di una paziente con allestimento del memoriale difensivo. Ruolo nella procedura di selezione dei candidati per l'assegnazione di incarichi libero professionali a medici Specialisti in M.I. in tre occasioni consecutive (anni 2014 -2017) Esperienza nella gestione dei pazienti immunodepressi per trapianto di organo solido. Attività di assistenza in reparto di M infettive Attività nell'ambulatorio tubercolosi per 3 anni. <u>Implementazioni di nuove attività</u> Implementazione del progetto di Regione Lombardia : "Progetto pilota per l'erogazione di servizi per la presa in carico territoriale delle persone che vivono con HIV" 2025 Implementazione del dosaggio plasmatico dei farmaci antiretrovirali, in collaborazione con il Laboratorio di Analisi, sia per i pazienti degenti che per quelli ambulatoriali. 2014 Organizzazione del percorso, la gestione e la terapia delle donne gravide con infezione da HIV in un team multidisciplinare (ostetrici/pediatri/neonatologi) presso hpg23. 2013
--	--

ESPERIENZA LAVORATIVA	
• Date (da – a)	Maggio 1998 ad Agosto 1999
• Nome e indirizzo del datore di lavoro	Azienda Ospedaliera di Chiari, Brescia,.
• Tipo di azienda o settore	AZIENDA SOCIO SANITARIA TERRITORIALE
• Tipo di impiego	Medico
• Principali mansioni e responsabilità	Medico in PS e internista per Medicina

ISTRUZIONE E FORMAZIONE	
• Date	1994-1999:
• Nome e tipo di istituto di istruzione o formazione	Scuola di Specialità in Malattie Infettive (full mark 50/50). Thesis: Immunological and virological benefit of HAART in an unselected cohort of naive HIV-infected patients after 1 year follow up. Università degli Studi di Brescia, Facoltà di Medicina e Chirurgia. Brescia, ITALY.
• Principali materie / abilità professionali oggetto dello studio	Specialista in Malattie Infettive e Tropicali. Gestione dei clinical trials sui farmaci antiretrovirali. Gestione cartella informatizzata in ambulatorio.
• Qualifica conseguita Livello nella classificazione nazionale (se pertinente)	Specialista in Malattie Infettive e Tropicali.

ISTRUZIONE E FORMAZIONE	
• Date	Marzo 1993
• Nome e tipo di istituto di istruzione o formazione	Università degli Studi di Brescia, Facoltà di Medicina e Chirurgia. Brescia, ITALY.
• Principali materie / abilità professionali oggetto dello studio	Medicina (Full marks. 110/110 cum laude). Thesis: "Risk factors for infections in heart transplant recipients."
• Qualifica conseguita	Laurea in Medicina e Chirurgia.

ISTRUZIONE E FORMAZIONE	
• Date (da – a)	Luglio 1984
• Nome e tipo di istituto di istruzione o formazione	Liceo Scientifico "F. Lussana". Bergamo, ITALY
• Principali materie / abilità professionali oggetto dello studio	Liceo Scientifico (votazione 58/60)
• Qualifica conseguita	Diploma di Scuola Secondaria

CORSI DI FORMAZIONE PROFESSIONALE	
Data 2014-2015	Corso di Direzione di Unità Ospedaliera (by CREMS). Milan. Italy, 2015
Edizione 13 dicembre 2012.	Il medico e i collaboratori, responsabilità civile e penale, i principali adempimenti. Edizione Milano
23 novembre 2012	Modalità di finanziamento dei ricoveri ospedalieri (il sistema dei DRG). Edizione Cremona
Edizione annuale, dal 2007 al 2017.	International Course on Clinical Pharmacology of Antiretrovirals. Università di Torino, Italy. (A total of 10 Editions),
Data 2006	6th Course: HIV management. The New York Course. New York, USA.
Data 2005	Multivariate statistic. Istituto Mario Negri. Villa Camozzi, Ranica - Bergamo, 2005
Data 4-9 June 2002.	Mediterranean School of Epidemiology and Statistical methods in Biomedical Research. (Phase 2) . Istituto Superiore di Sanità Siracusa. Italy
Data 1-15 Sep 2001.	Mediterranean School of Epidemiology and Statistical methods in Biomedical Research. (Phase 1) . Istituto Superiore di Sanità. Crotone, Italy
Data 29 May 2001	Prex International HIV Training Program at the University of California San Francisco, San Francisco General Hospital, San Francisco, USA.
data 25-29 March 1996.	Stage in Principles of statistical methodology for clinical investigation. Milan

Totale crediti ECM	Triennio	Crediti conseguiti/richiesti
Fonte CO.GE.A.P.S. (Maggio 2025)	2023-25	232.7/70
	2020-22	203.5/46.7
	2017-19	354.4/90
	2014-16	355.2/105
	2011-13	274.5/105
	2008-10	161/0
	2005-07	88/0
	2002-04	91/0

COMPETENZE SCIENTIFICHE

Open Researcher and Contributor ID

ORCID ID: 0000-0001-6702-6668

H index: 31, Research Gate (June 2025)

<https://www.researchgate.net/profile/Diego-Ripamonti>

Attività Editoriale

- **Associate Editor** per FRONTIERS IN MEDICINE in *Infectious Diseases: Pathogenesis and Therapy*
<https://www.frontiersin.org/my-frontiers/overview> dal Febbraio 2021 al 2025:

n. 38 publications edited + 3 Research Topics

- ✓ Guest Associate Editor in *Infectious Diseases: Epidemiology and Prevention*. (2023) **Research Topic Editor**: World AIDS Day 2022: Putting ourselves to the test: achieving equity to end HIV. *Frontiers in Public Health*
- ✓ Guest Associate Editor in *Life-Course Epidemiology and Social Inequalities in Health* (2023). **Research Topic Editor**: Exploring HIV Disclosure Challenges and Approaches Around the Globe. *Frontiers in Public Health*. *Infectious Diseases: Epidemiology and Prevention*. *Life-Course Epidemiology and Social Inequalities in Health*.
- ✓ Guest Associate Editor in *Infectious Disease Epidemiology*. **Research Topic Editor** (2024) of "Towards Control of the HIV epidemic: Trends in Epidemiology and Emerging Drug Resistance in the Integrase Inhibitor Era".

- **Guest Editor** di *Journal of Clinical Medicine* per lo Special issue "Heart Disease Complicated by HIV Infection: Predictors, Diagnosis and Treatment Options".
https://www.mdpi.com/journal/jcm/special_issues/R6KI7O320E

- **Guest Editor** for *Cancers*, Special Issue "Cancers in chronic HIV infection".
https://www.mdpi.com/journal/cancers/special_issues/T464M252R1

Attività di reviewer per riviste scientifiche internazionali

Riviste di ambito infettivologico:

- ✓ Viruses IF: 4.7
- ✓ Scientific Reports IF: 4.9
- ✓ BMC Infectious Diseases IF: 3.4
- ✓ HIV Medicine IF: 3.09
- ✓ Frontiers in Medicine: *HIV Pathogenesis and Treatment* IF: 3.1
- ✓ Discover Public Health IF: 2.4
- ✓ AIDS Research and Therapy IF: 2.1
- ✓ Medicine IF: 1.4
- ✓ Tropical Medicine and Infectious Disease. IF 2.8
- ✓ Pathogens IF: 3.7
- ✓ PLoS One IF: 3.24

Attività di organizzazione e relatore per meetings scientifici

- ✓ Responsabile scientifico del meeting "The why and the wherefores in HIV therapy", Bergamo, Aprile 2025
- ✓ Responsabile scientifico per: "Webinar on HIV and Cardiovascular diseases: how can we face this challenge?" organizzato con *Journal of Clinical Medicine* nel 2024.
- ✓ Partecipazione in 10 Advisory Boards sulle strategie antiretrovirali, in Italia e in Europa, negli ultimi 10 anni.
- ✓ Relatore in oltre 50 meetings, convegni, e congressi scientifici dal 2014 ad oggi sulla terapia antivirale

Attività di ricerca scientifica presso HPG23

Ho partecipato dal 2003 alla implementazione di numerosi trials clinici presso hpg23 con ruoli diversi: *scrittura di protocolli, arruolamento dei pazienti, gestione amministrativa, visita pazienti e monitoraggio, AUDIT, presentazione ai congressi e scrittura di lavori scientifici.*

Studi clinici spontanei e sponsorizzati dal 2001 presso HPG23

1. DoDaco Study. Studio spontaneo di coorte nazionale terapia HIV, come **coordinatore** del progetto (2024)
2. VOGUE study HIV therapy - phase III trial, as **principal** investigator (2024)
3. Remdesivir study in COVID-19 (Gilead), phase III trial, as **principal** investigator
4. DIAMANTE study (Janssen), phase III trial, switch trial in HIV infections as **principal** investigator
5. STORE study (Janssen), phase III trial, DRV-cobicistat, as **principal** investigator
6. PROTEA study (Janssen), phase III trial, DRV monotherapy, as **principal** investigator
7. MONET Study (Janssen), phase III trial, DRV monotherapy as **principal** investigator
8. Pharmacogenetic Study on abacavir hypersensitivity, (GSK), as coinvestigator

9. Atazanavir/rtv in HIV pregnant women (*spontaneous*), PK study, as **principal** investigator.
10. TMC125-C217 Study (*Tibotec*), salvage regimen, phase III trial, as coinvestigator
11. TMC114-C214 Study (*Tibotec*), salvage regimen, phase III trial, as coinvestigator
12. Tucaresol Study (*GSK*), immune modulator, phase III trial, as coinvestigator
13. LOTTI Study (*ISS*), STI strategy, phase III trial, as coinvestigator
14. TASTE Study(*spontaneous*), thymidine-sparing regimen, phase III trial, as coinvestigator
15. KISS Study(*spontaneous*), HAART in naïve patients, phase III trial, as coinvestigator
16. Basta Study (*spontaneous*), STI strategy, phase III trial, as coinvestigator
17. TEDAL Study (*spontaneous*), HAART in naïve patients, phase III trial, as coinvestigator
18. SILCAAT Study (*DHHS*), immune modulator, phase III trial, as coinvestigator
19. PART Study (*ISS*), STI strategy, phase III trial, as coinvestigator

Membro di Società Scientifiche

- ✓ SIMIT (Società Italiana di Malattie Infettive)
- ✓ European AIDS Clinical Society (EACS)
- ✓ Member of Faculty di ICAR (Italian Conference on AIDS and Antiviral Research)

Gruppi di lavoro

- ✓ The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an **Italian expert panel** perspective for the long-term management of HIV-1 infection. (2012)
- ✓ **Italian Panel** for Antiretroviral Guidelines in adults and children (2017)
- ✓ **Italian expert panel** consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients (2019)

Esperienza di insegnamento

- ✓ Speaker negli ultimi 10 anni in oltre 50 meetings (HIV therapy, infezioni fungine e terapie dei batteri multi-drug-resistant nell'ambito di programmi ECM).
- ✓ Docente per Corso AIDS per Dirigenti Medici. Lodi, 2018
- ✓ Relatore all'aggiornamento per gli **specializzandi** in Malattie Infettive (Progetto di formazione Pandora presso l'Università di Milano, coordinatore scientifico Prof. Spinello Antinori). Anno 2024
- ✓ Relatore presso le **giornate scientifiche di SIMIT**, Lombardia 2023-24
- ✓ Docente in 2 edizioni presso **"International Course on Clinical Pharmacology of Antiretrovirals"**. Turin, Italy", International Residential course, coordinato dal Prof. Giovanni Di Perri.
- ✓ Speaker in 3 Ospedali a **Londra** nel 2019 sulla strategia antiretrovirale.
- ✓ Speaker presso World Congress of Virus and Infection sul tema "Antiretrovirals and resistance". Busan, 2010
- ✓ Docenza per "Emergenza infettive e revisione dei protocolli aziendali di prevenzione e controllo". 2016
- ✓ Docenza nel corso di formazione "Aggiornamento Professionale per Infermieri". anno 2006, 2007, 2008

- ✓ Tutor alla stage di INFEZIONI OSPEDALIERE. 2011
- ✓ Multidisciplinary Team per la **Sepsis Surveillance Campaign** (SSC) presso hpg23
- ✓ Tutor nel programma di "Healthcare associated infections and emergence of MDR bacteria" presso ASST-pg23 nel 2012 - 2014.
- ✓ Speaker at "Evaluation and use of Medicinal Product during pregnancy". 2nd Edition, 2007. Ginevra
- ✓ **Coordinamento degli studenti di medicina** nel training, preparazione tesi e correlatore tesi per esami di laurea in medicina e di specialità in Malattie infettive (Università Bicocca e Università di Milano)
- ✓ **Responsabile per la organizzazione** del corso di aggiornamento annuale su HIV e immunodeficit dal 2012 ad oggi (aggiornamento obbligatorio degli specialisti di Malattie Infettive).

PUBBLICAZIONI SCIENTIFICHE

Major Topics: ✓ terapia HIV (nuovi regimi, tossicità metabolica, resistenza genotipica, popolazioni difficili, stigma sociale) ✓ farmacocinetica degli antiretrovirali ✓ terapia antivirale in gravidanza ✓ terapia per HBV ✓ terapia per HCV ✓ epatossicità degli antivirali ✓ vaccinazioni negli immunocompromessi ✓ malattia COVID-19 ✓ tubercolosi e BCGite ✓ tripanosomiasi africana	
Evidenziate le pubblicazioni più significative in ambito infettivologico	Contributo*
1. Changes in CD8+ T-cell activation after switching from suppressive 3-drug to 2-drug cART in people with HIV. 17th ICAR, Padua May 2025. Oral presentation 2. Long-term durability of dolutegravir/lamivudine dual regimen in a real-world setting (Dolu3TC study). 17th ICAR, Padua May 2025. Oral presentation 3. STI occurrence among PrEP users: a six-year follow-up study from the Bergamo centre. 17th ICAR, Padua May 2025. Oral presentation 4. Characteristics of people living with HIV who were lost to follow-up. 17th ICAR, Padua May 2025. Oral presentation 5. Up to half of geriatric people living with HIV are treated with 2-drug INSTI-based regimens. 17th ICAR, Padua May 2025. Poster P106 6. Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study). J Antimicrob Chemother. 2025 Apr 9:dkaf119. 7. Durability of doravirine-dolutegravir dual combination in a multicenter cohort of elderly people with HIV J Antimicrob Chemother. 2025 Apr 2;80(4):1089-1096 8. Impact of PrEP cost on prophylaxis initiation in an Italian centre. ICAR 2024. Oral presentation, SC 13 9. World AIDS Day 2022: putting ourselves to the test: achieving equity to end HIV. Front Public Health. 2024;12:1478645 10. Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine.	First author, A,C First author, A,C Co-author, B,E Co-author, B,E First- author, A,C First author, A,C Co-author, B,E Co-author, B,E First- author, A,C First author, A,C

Journal of Antimicrobial Chemotherapy 2024 ;	
11. Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. <i>Brain</i> 2024 ;147:3742–3750	Co-author, B,E
12. Exploring HIV disclosure challenges and approaches around the globe. <i>Front. Public Health</i> , 09 January 2024 . Volume 11	Co-author, A,C
13. A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine. <i>AIDS</i> . 38 (2):263-265, February 01, 2024	First author , A,C
14. Emergent HIV drug resistance in non-inferiority trials. <i>Lancet HIV</i> . 2023 ;10:e632-e634.	First author , A,C
15. Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE. <i>Sci Rep</i> . 2023 ;17;13:17624	Co-author, B,E
16. Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study. <i>Future Virol</i> 2023 : 10.2217/fvl-2023-0065	Co-author, B,E
17. Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. <i>Sex Transm Infect</i> . 2023 Feb;99(1):53-56.	Co-author, B,E
18. HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (IN ACTION) clinical trial. <i>J Med Virol</i> . 2023 ;95(9):e29114.	Co-author, B,E
19. Vascular graft infections caused by <i>Mycobacterium bovis</i> BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature. <i>J Clin Tuberc Other Mycobact Dis</i> . 2023 Mar 8;31:100360.	Co-author, B,E
20. Perceptions of U = U Among Italian Infectious Diseases Specialists: A Nationwide Survey on Providers' Attitudes Toward the Risk of HIV Transmission in Virologically Suppressed Patients. <i>AIDS Res Hum Retroviruses</i> . 2022 Oct 11.	First author , A,C
21. Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study. <i>Medicine (Baltimore)</i> . 2022 Jul 29;101(30):e29855.	Co-author, B,E
22. The changing pattern of bacterial and fungal respiratory isolates in patients with and without COVID-19 admitted to intensive care unit. <i>BMC Infect Dis</i> . 2022 Feb 23;22(1):185.	Co-author, B,E
23. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. <i>Leukemia</i> . 2021 Sep;35(9):2710-2714. doi: 10.1038/s41375-021-01299-x. Epub 2021 May 24.	Co-author, B,E
24. Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infect Dis</i> . 2021 26;8(7):ofab278. eCollection 2021 Jul.	Co-author, A,B,E
25. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. <i>J Transl Med</i> . 2020 Oct 21;18(1):405.	Co-author, B,E
26. Potential role of subcutaneous tocilizumab injections in patients with COVID-19 associated pneumonia. <i>J Med Virol</i> . 2020 Sep 8	Co-author, B,E
27. SARS-CoV-2 infection in persons living with HIV: A single center prospective cohort. <i>J Med Virol</i> . 2020 Jul 24;10.1002/jmv.26352. doi: 10.1002/jmv.26352.	Co-author, B,E
28. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV Infection (IN ACTION) cohort. <i>HIV Med</i> . 2020 Sep;21(8):523-535.	Co-author, B,E
29. Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV Infection (IN ACTION) Retrospective Study. <i>Pathog Immun</i> . 2020 Feb 24;5(1):8-33	Co-author, B,E
30. Effectiveness of switching to darunavir/cobicistat in virologically-suppressed HIV-positive patients receiving ritonavir-boosted protease inhibitor-based regimen: the "STORE" Study. <i>J Acquir Immune Defic Syndr</i> . 2020 Feb 24.	Co-author, B,E
31. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clin Exp Rheumatol</i> . 2020 Mar-Apr;38(2):245-256.	Co-author, B,E
32. Cutaneous mucormycosis by <i>Rhizopus arrhizus</i> treated with isavuconazole as first line therapy: A case report. <i>Med Mycol Case Rep</i> . 2019 ;26:42-43	Co-author, B,E
33. Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. <i>New Microbiol</i> . 2019 ;42(2):69-80.	Co-author, E
34. Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studies. <i>AIDS</i> . 2018 ;32:835-840.	First author , A,B,C
35. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis? <i>AIDS Res Hum Retroviruses</i> . 2018 ;34:168-170	Co-author, B,E
36. Novelties in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success? <i>AIDS Rev</i> .	Co-author, B

2017;19:119-133	
37. Autoimmune hepatitis and HIV infection: two case reports and review of the literature. <i>AIDS</i> . 2017 ;31:2172-2175	Co-author, B,E
38. PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS One</i> . 2017 ;12:e0181433	Co-author, B,E
39. Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. <i>Clin Infect Dis</i> . 2017 ;64:1198-1203	Co-author, B,C,E
40. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. <i>BMC Infect Dis</i> . 2017 ;17:215.	Co-author, B,C
41. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. <i>J Clin Virol</i> . 2017 ;87:30-36.	Co-author, B,C
42. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial. <i>HIV Med</i> . 2017 ;18:5-12	First author, A,B,C
43. Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection. <i>Evid Based Med</i> . 2016 ;21:184	First author, B,C,E
44. Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). <i>New Microbiol</i> . 2016 ;39:290-294	Co-author, B,C
45. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. <i>PLoS Med</i> . 2015 ;12:e1001809	Co-author, B,C
46. Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates. <i>J Chemother</i> 2016 ;28:337-40.	Co-author, C,E
47. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. <i>AIDS</i> 2015 ;29:1811-20	Co-author, B,C,E
48. Ageing with HIV: a multidisciplinary review. <i>Infection</i> . 2015 ;43:509-22	Co-author, C,E
49. Pulmonary complications associated with pegylated interferon and ribavirin in HIV/hepatitis C virus coinfecting patients. <i>AIDS</i> . 2014 ;28:2633-5	First author, A,B,C
50. Brain abscess. <i>N Engl J Med</i> . 2014 Oct 30;371(18):1756-7.	Co-author, A,B,C
51. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience. <i>HIV Clin Trials</i> . 2014 ;15:140-50.	Co-author, B,C,E
52. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. <i>J Am Heart Assoc</i> . 2014 ;3:e000844.	Co-author, C,E
53. Do lopinavir and ritonavir require a dose adjustment during pregnancy? <i>J Acquir Immune Defic Syndr</i> . 2014 Jul 1;66(3):e64-5	First author, A,B,C
54. Drug reaction with eosinophilia and systemic symptoms (DRESS) associated to raltegravir use. Case report and review of the literature. <i>AIDS</i> 2014 ;	Co-author, C,E
55. Abacavir-induced liver toxicity in an HIV infected patient. <i>AIDS</i> 2014 ;	Co-author, A,B,C
56. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase inhibitor against HIV. <i>Expert Review of Anti-infective Therapy</i> 2014 ;12:13-29	First author, B,E
57. Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success? <i>AIDS Rev</i> . 2013 ;15(4):230-6.	First author, A,B,C
58. Unboosted Atazanavir for Treatment of HIV Infection: Rationale and Recommendations for Use. <i>Drugs</i> . 2012 ; 18;72:1161-73.	Co-author, B
59. The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. <i>New Microbiol</i> . 2012 ; 35:259-77.	Co-author, B,C,E
60. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. <i>Eur Rev Med Pharmacol Sci</i> . 2012 ;16:1473-83. Review.	Co-author, B,C,E
61. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. <i>Infection</i> . 2011 Jan 19.	Co-author, B,C
62. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. <i>Ther Drug Monit</i> . 2010 ;32(6):782-6.	Co-author, B,C
63. Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. <i>Curr HIV Res</i> . 2010 ;8(3):186-93.	Co-author, B,C
64. Transplacental passage of darunavir in two pregnant women. <i>International Journal of STD & AIDS</i> 2009 ;20:215-6.	First author, A,B,C,E
65. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained	

immunologic response to HAART. <i>AIDS</i> 2009 ;27:799-807	Co-author A,B,C
66. Interleukin-2 therapy in patients with HIV infection. <i>N Engl J Med.</i> 2009 ;361(16):1548-59.	Co-author, B,C
67. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. <i>Curr Opin Investig Drugs</i> 2008 ;9:899-912	First author A,B,C
68. Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection. <i>J Chromatogr Sci</i> 2008 ;46:485-9.	Co-author, B,C
69. Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. <i>AIDS</i> 2008 ;22:1236-7.	First author A,B,C
70. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. <i>AIDS.</i> 2007 ;21:2409-15	First author A,B,C
71. Prediction of Virologic Outcome of Salvage Antiretroviral Treatment by Different Systems for Interpreting Genotypic HIV Drug Resistance. <i>J Int Assoc Physicians AIDS Care.</i> 2007 ;6:87-93.	Co-author, A,B,C
72. Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman. <i>AIDS.</i> 2007 ;21:1059-60	First author A,B,C
73. Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort. <i>HIV Clin Trials.</i> 2007 ;8:9-18	Co-author, A,B,C
74. Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. <i>J Antimicrob Chemother</i> 2007 ;59:569-72.	Co-author, B,C
75. The Trivacan study. Letter to the Editor. <i>Lancet.</i> 2006 ;368:915;	Co-author, B,C
76. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. <i>Antivir Ther.</i> 2006 ;11:923-9	First author, A,E
77. Switch strategies in patients on effective HAART. <i>J Antimicrob Chemother</i> 2005 ;55:821-3.	Co-author B,C
78. Reply to Vidal et al. <i>Clin Infect Dis</i> 2005 ;40:1072-1073	First author, A,E
79. Quadruple-drug induction HAART in advanced HIV infection. <i>HIV Clin Trials</i> 2005 ;6:1-4.	Co-author, B,C,E
80. "Similar adherence rates favour different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors". <i>Clin Infect Dis</i> 2005 ;40:158-63.	First author A,C
81. "New Times for an Old Disease: Intracranial Mass Lesions Caused by <i>Mycobacterium tuberculosis</i> in 5 HIV-Negative African Immigrants". <i>Clin Infect Dis</i> 2004 ;39:e35-e45	First author A,C
82. "HIV-1 and hepatitis B virus: time for a re-think?". <i>Lancet</i> 2004 ;363:1400	First author A,B,C
83. "Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial". <i>AIDS</i> 2004 ;18:439-46.	Co-author, B,C
84. "Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients". <i>AIDS</i> 2004 ;18:334-7	Co-author, B,C
85. The changing spectrum of respiratory infections in HIV-1 infected patients in the era of highly active antiretroviral therapy. <i>Minerva Pneumologica</i> 2004 ;43:1-30	First author A,B,C
86. "Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmacoeconomic implications in a population-based setting". <i>Health Policy</i> 2003 ;65:261-7	Co-author, B,C
87. "Once-a-day therapy for HIV infection: a controlled, randomised study in antiretroviral-naïve HIV-1 infected patients". <i>Antiviral Therapy</i> 2003 ;8:339-346	Co-author, B,C
88. "Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection". <i>Clin Infect Dis.</i> 2003 ;37:41-9	Co-author, B,C
89. "Once a day therapy: dream or reality?". <i>HIV Clin Trials</i> 2003 ;	Co-author, B,C
90. "Resolution of lymphocytic interstitial pneumonia in a human immunodeficiency virus-infected adult following the start of highly active antiretroviral therapy". <i>Scand J Infect Dis.</i> 2003 ;35(5):348-51	First author, B,E
91. "Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling. <i>Antiviral Therapy</i> 2003 ;8:121-126	Co-author, B,C
92. "Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology and outcome. <i>JAIDS</i> 2003 ;32:259-267	Co-author, B,C
93. "Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. <i>HIV Clin Trials</i> 2002 ;3:371-8.	Co-author, B,E
94. "Abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-positive patients". <i>AIDS</i> 2002 ;16:1981	Co-author, B,C
95. "Cluster of Africa trypanosomiasis in travellers to Tanzanian national parks". <i>Emerg Infect Dis</i> 8(6), 2002	Co-author, B,C,E
96. "Factors associated with the failure of HIV-positive persons to return for scheduled medical visits". <i>HIV Clin Trials.</i> 2002 ;3:52-57.	Co-author, B,E
97. "Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant	First author A,B,C

viruses" AIDS 2002 ;16:298-299	
98. "Discordant immunological response in HIV positive patients on non-nucleoside-reverse-transcriptase-inhibitor-based-regimens". AIDS 2002 ;16:130-131	First author B,C
99. "African sleeping sickness in tourists returning from Tanzania: the first two Italian cases from a small outbreak among European travellers". Clin Infect Dis 2002 ;34:e18-22	First author A,B,C
100. "Estimating duration of HIV infection with CD4 count and HIV-1 RNA at presentation". AIDS 2001 ; 15:2001-3	First author A,B,C
101. "Long term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution". Int Journal of STD & AIDS 2001 ;12:573-581	Co-author, B,E
102. "Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART". International Journal of STD & AIDS 2001 ;12:407-409	Co-author, B,E
103. Changing patterns of HIV transmission and better targeting for intervention strategies. Int STD AIDS 1998 ;9(12):740-3	First author A, B,C
104. Cholestatic liver disease and thrombocytopenia associated with long exposure to ticlopidine. Minerva Gastroenterol Dietol. 1998 ;44(4):211-4.	First author A,B,C
105. Impiego delle nuove strategie antiretrovirali e impatto sui costi globali dell'AIDS". Giornale Italiano di Malattie Infettive, 1999 Vol. 5; Suppl 1: S40-S46	Co-author B,E
	First author A, B,C

* *Legenda for contribution evaluation:*

A: concept, B: data collection, C: writing, D: statistical analysis, E: critical revision

PRIMA LINGUA	italiano		
ALTRE LINGUE			
	INGLESE	FRANCESE	SPAGNOLO
• Capacità di lettura*	ottima		
• Capacità di scrittura*	ottima		
• Capacità di espressione orale*	ottima		

*sufficiente/discreta/buona/ottima

in alternativa:

A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato (Quadro Comune Europeo di Riferimento delle Lingue)

CAPACITÀ E COMPETENZE RELAZIONALI <i>Indicare ambiti e ruoli richiesti ove la comunicazione è importante ed essenziale per lavorare in squadra (settori cultura, sportivi...)</i>	Attività di coordinamento del gruppo di persone coinvolte negli aspetti amministrativi/clinici/gestionali degli studi clinici. Organizzazione di meeting scientifici ECM
---	---

CAPACITÀ E COMPETENZE ORGANIZZATIVE <i>Coordinamento risorse umane, progettualità, attività di volontariato....</i>	Implementazione di studi clinici spontanei Attività di coordinamento di ricerca finalizzata a livello nazionale Organizzazione di Webinar on line nazionali e internazionali Responsabile scientifico di meeting ECM con elaborazione dei contenuti e coordinamento dei relatori.
---	--

CAPACITÀ E COMPETENZE TECNICHE <i>Con computer, attrezzature specifiche, macchinari, ecc.</i>	Utilizzo di strumenti informatici: Word, Power Point, Excell, Access . Attrezzature: Utilizzo di Fibroscan
---	---

CAPACITÀ E COMPETENZE ARTISTICHE	
---	--

<i>Musica, scrittura, disegno ecc.</i>		
PATENTE O PATENTI		
ALLEGATI		

"Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.

Il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal Regolamento UE n. 679/2016 – GDPR General Data Protection Regulation, D.Lgs 196/2003 modificato da D.Lgs 101/2018."

Bergamo, 11/06/2025

NOME E COGNOME (FIRMA)
Diego Ripamonti